Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab beta for MOG antibody-positive optic neuritis
ChiCTR2600132519Phase 4Not yet recruiting
- Sponsor
- Eye Hospital of Wenzhou Medical University
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of obinutuzumab beta in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis (MOG-ON) (2 arms), sponsored by Eye Hospital of Wenzhou Medical University. Primary endpoint: annualized optic neuritis relapse rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
obinutuzumab beta
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated optic neuritis (MOG-ON)
Beyond the preview
Go deeper on ChiCTR2600132519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132519.